Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 178


The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.

Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Protopopov A, Li J, Kashuba V, Klein G, Zabarovsky ER.

Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7504-9. Epub 2001 Jun 5.


Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.

Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F, Maher ER.

Cancer Res. 2001 Oct 1;61(19):7277-81.


Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma.

Hogg RP, Honorio S, Martinez A, Agathanggelou A, Dallol A, Fullwood P, Weichselbaum R, Kuo MJ, Maher ER, Latif F.

Eur J Cancer. 2002 Aug;38(12):1585-92.


Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).

Singh RB, Amare Kadam PS.

Urol Oncol. 2013 Oct;31(7):1333-42. doi: 10.1016/j.urolonc.2011.08.012. Epub 2011 Oct 1.


Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.

Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M, Croce CM.

Cancer Res. 2003 Jul 1;63(13):3724-8.


Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers.

Yu MY, Tong JH, Chan PK, Lee TL, Chan MW, Chan AW, Lo KW, To KF.

Int J Cancer. 2003 Jun 10;105(2):204-9.


RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.

Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HP, Voutilainen R, Dahia P, Eng C, Maher ER, Latif F.

Oncogene. 2001 Nov 8;20(51):7573-7.


Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.

Agathanggelou A, Dallol A, Zöchbauer-Müller S, Morrissey C, Honorio S, Hesson L, Martinsson T, Fong KM, Kuo MJ, Yuen PW, Maher ER, Minna JD, Latif F.

Oncogene. 2003 Mar 13;22(10):1580-8.


RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma.

Chow LS, Lo KW, Kwong J, To KF, Tsang KS, Lam CW, Dammann R, Huang DP.

Int J Cancer. 2004 May 10;109(6):839-47.


Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours.

Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER, Latif F.

Oncogene. 2001 Mar 22;20(12):1509-18.


Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors.

Horiguchi K, Tomizawa Y, Tosaka M, Ishiuchi S, Kurihara H, Mori M, Saito N.

Oncogene. 2003 Oct 30;22(49):7862-5.


Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma.

Tokinaga K, Okuda H, Nomura A, Ashida S, Furihata M, Shuin T.

Oncol Rep. 2004 Oct;12(4):805-10.


Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.

Lee MG, Kim HY, Byun DS, Lee SJ, Lee CH, Kim JI, Chang SG, Chi SG.

Cancer Res. 2001 Sep 15;61(18):6688-92.


Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer.

Wagner KJ, Cooper WN, Grundy RG, Caldwell G, Jones C, Wadey RB, Morton D, Schofield PN, Reik W, Latif F, Maher ER.

Oncogene. 2002 Oct 17;21(47):7277-82.


[Development of human renal cell carcinoma (RCC)--the responsible genes for the development of hereditary and sporadic human RCCs].

Shuin T, Kamata M, Ashida S.

Gan To Kagaku Ryoho. 2002 Oct;29(10):1719-25. Japanese.


Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas.

Yoon JH, Dammann R, Pfeifer GP.

Int J Cancer. 2001 Oct 15;94(2):212-7.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk